Lipid mediators as regulators of human ILC2 function in allergic diseases

Immunology Letters

Volumn 179, Issue , 2016, Pages 36-42

  Konya, Viktoria ^a,b   Mjösberg, Jenny ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Asthma; Atopic dermatitis; Innate lymphoid cells; Leukotrienes; Lipoxins; Prostaglandins

Indexed keywords

ANTIALLERGIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; CRTH2 ANTAGONIST; DUPILUMAB; FPR2 RECEPTOR AGONIST; INTERLEUKIN 4 ANTIBODY; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPID; LIPOXIN; LONG ACTING DRUG; MEPOLIZUMAB; PROSTAGLANDIN; SHORT ACTING DRUG; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; AUTACOID;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ARTICLE; ATOPIC DERMATITIS; CELL ACTIVITY; CELL FUNCTION; CELL MATURATION; CELL SUBPOPULATION; CELLULAR PARAMETERS; CYTOKINE PRODUCTION; CYTOLOGY; DRUG TARGETING; ENERGY METABOLISM; GROUP 2 INNATE LYMPHOID CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LIPOGENESIS; LYMPHOID CELL; METABOLIC REGULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; SKIN ALLERGY; CELL PLASTICITY; DRUG EFFECTS; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTI-ASTHMATIC AGENTS; CELL PLASTICITY; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; LEUKOTRIENES; LIPIDS; LIPOXINS; LYMPHOCYTE SUBSETS; MOLECULAR TARGETED THERAPY; PROSTAGLANDINS;

EID: 84993233972     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.07.006     Document Type: Article

References (117)

1. [1] Spits, H., Cupedo, T., Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30 (2012), 647–675.
2. [2] Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G., Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius, R.E., Powrie, F., Vivier, E., Innate lymphoid cells – a proposal for uniform nomenclature. Nat. Rev. Immunol. 13:2 (2013), 145–149.
3. [3] Bjorkstrom, N.K., Ljunggren, H.G., Michaelsson, J., Emerging insights into natural killer cells in human peripheral tissues. Nat. Rev. Immunol. 16:5 (2016), 310–320.
4. [4] Gasteiger, G., Ataide, M., Kastenmuller, W., Lymph node – an organ for T-cell activation and pathogen defense. Immunol. Rev. 271:1 (2016), 200–220.
5. [5] McKenzie, A.N., Type-2 innate lymphoid cells in asthma and allergy. Ann. Am. Thorac. Soc. 11:Suppl. 5 (2014), S263–S270.
6. [6] Halim, T.Y., Group 2 innate lymphoid cells in disease. Int. Immunol. 28:1 (2016), 13–22.
7. [7] Mjosberg, J., Bernink, J., Golebski, K., Karrich, J.J., Peters, C.P., Blom, B., te Velde, A.A., Fokkens, W.J., van Drunen, C.M., Spits, H., The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37:4 (2012), 649–659.
8. [8] Bartemes, K.R., Iijima, K., Kobayashi, T., Kephart, G.M., McKenzie, A.N., Kita, H., IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J. Immunol. 188:3 (2012), 1503–1513.
9. [9] Prefontaine, D., Nadigel, J., Chouiali, F., Audusseau, S., Semlali, A., Chakir, J., Martin, J.G., Hamid, Q., Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 125:3 (2010), 752–754.
10. [10] Zhang, Y., Zhou, B., Functions of thymic stromal lymphopoietin in immunity and disease. Immunol. Res. 52:3 (2012), 211–223.
11. [11] Karta, M.R., Broide, D.H., Doherty, T.A., Insights into group 2 innate lymphoid cells in human airway disease. Curr. Allergy Asthma Rep., 16(1), 2016, 8.
12. [12] Sharma, J., Balakrishnan, L., Datta, K.K., Sahasrabuddhe, N.A., Khan, A.A., Sahu, A., Singhal, A., Getnet, D., Raju, R., Chatterjee, A., Gowda, H., Keshava Prasad, T.S., Shankar, S., Pandey, A., A knowledgebase resource for interleukin-17 family mediated signaling. J. Cell Commun. Signal. 9:3 (2015), 291–296.
13. [13] Bartemes, K.R., Kephart, G.M., Fox, S.J., Kita, H., Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J. Allergy Clin. Immunol. 134:3 (2014), 671–678 e4.
14. [14] Bal, S.M., Bernink, J.H., Nagasawa, M., Groot, J., Shikhagaie, M.M., Golebski, K., van Drunen, C.M., Lutter, R., Jonkers, R.E., Hombrink, P., Bruchard, M., Villaudy, J., Munneke, J.M., Fokkens, W., Erjefalt, J.S., Spits, H., Ros, X.R., IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat. Immunol., 2016.
15. [15] Ohne, Y., Silver, J.S., Thompson-Snipes, L., Collet, M.A., Blanck, J.P., Cantarel, B.L., Copenhaver, A.M., Humbles, A.A., Liu, Y.J., IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat. Immunol., 2016.
16. [16] Yu, X., Pappu, R., Ramirez-Carrozzi, V., Ota, N., Caplazi, P., Zhang, J., Yan, D., Xu, M., Lee, W.P., Grogan, J.L., TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol. 7:3 (2014), 730–740.
17. [17] Doherty, T.A., Khorram, N., Lund, S., Mehta, A.K., Croft, M., Broide, D.H., Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J. Allergy Clin. Immunol. 132:1 (2013), 205–213.
18. [18] Barnig, C., Cernadas, M., Dutile, S., Liu, X., Perrella, M.A., Kazani, S., Wechsler, M.E., Israel, E., Levy, B.D., Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med., 5(174), 2013 174ra26.
19. [19] Xue, L., Salimi, M., Panse, I., Mjosberg, J.M., McKenzie, A.N., Spits, H., Klenerman, P., Ogg, G., Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J. Allergy Clin. Immunol. 133:4 (2014), 1184–1194.
20. [20] Chang, J.E., Doherty, T.A., Baum, R., Broide, D., Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J. Allergy Clin. Immunol. 133:3 (2014), 899–901 e3.
21. [21] Wojno, E.D., Monticelli, L.A., Tran, S.V., Alenghat, T., Osborne, L.C., Thome, J.J., Willis, C., Budelsky, A., Farber, D.L., Artis, D., The prostaglandin D(2) receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol. 8:6 (2015), 1313–1323.
22. [22] Zhou, W., Toki, S., Zhang, J., Goleniewksa, K., Newcomb, D.C., Cephus, J.Y., Dulek, D.E., Bloodworth, M.H., Stier, M.T., Polosuhkin, V., Gangula, R.D., Mallal, S.A., Broide, D.H., Peebles, R.S. Jr., Prostaglandin I2 signaling and inhibition of group 2 innate lymphoid cell responses. Am. J. Respir. Crit. Care Med. 93:1 (2016), 31–42.
23. [23] Krishnamoorthy, N., Burkett, P.R., Dalli, J., Abdulnour, R.E., Colas, R., Ramon, S., Phipps, R.P., Petasis, N.A., Kuchroo, V.K., Serhan, C.N., Levy, B.D., Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. J. Immunol. 194:3 (2015), 863–867.
24. [24] Haeggstrom, J.Z., Funk, C.D., Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev. 111:10 (2011), 5866–5898.
25. [25] Fanning, L.B., Boyce, J.A., Lipid mediators and allergic diseases. Ann. Allergy. Asthma. Immunol. 111:3 (2013), 155–162.
26. [26] Honda, T., Tokura, Y., Miyachi, Y., Kabashima, K., Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology. Curr. Drug Targets 11:12 (2010), 1605–1613.
27. [27] Hoyler, T., Klose, C.S., Souabni, A., Turqueti-Neves, A., Pfeifer, D., Rawlins, E.L., Voehringer, D., Busslinger, M., Diefenbach, A., The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37:4 (2012), 634–648.
28. [28] Klose, C.S., Flach, M., Mohle, L., Rogell, L., Hoyler, T., Ebert, K., Fabiunke, C., Pfeifer, D., Sexl, V., Fonseca-Pereira, D., Domingues, R.G., Veiga-Fernandes, H., Arnold, S.J., Busslinger, M., Dunay, I.R., Tanriver, Y., Diefenbach, A., Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157:2 (2014), 340–356.
29. [29] Halim, T.Y., MacLaren, A., Romanish, M.T., Gold, M.J., McNagny, K.M., Takei, F., Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. Immunity 37:3 (2012), 463–474.
30. [30] Scoville, S.D., Mundy-Bosse, B.L., Zhang, M.H., Chen, L., Zhang, X., Keller, K.A., Hughes, T., Chen, L., Cheng, S., Bergin, S.M., Mao, H.C., McClory, S., Yu, J., Carson, W.E. 3rd, Caligiuri, M.A., Freud, A.G., A progenitor cell expressing transcription factor RORgammat generates all human innate lymphoid cell subsets. Immunity 44:5 (2016), 1140–1150.
31. [31] Wong, S.H., Walker, J.A., Jolin, H.E., Drynan, L.F., Hams, E., Camelo, A., Barlow, J.L., Neill, D.R., Panova, V., Koch, U., Radtke, F., Hardman, C.S., Hwang, Y.Y., Fallon, P.G., McKenzie, A.N., Transcription factor RORalpha is critical for nuocyte development. Nat. Immunol. 13:3 (2012), 229–236.
32. [32] Yang, Q., Monticelli, L.A., Saenz, S.A., Chi, A.W., Sonnenberg, G.F., Tang, J., De Obaldia, M.E., Bailis, W., Bryson, J.L., Toscano, K., Huang, J., Haczku, A., Pear, W.S., Artis, D., Bhandoola, A., T cell factor 1 is required for group 2 innate lymphoid cell generation. Immunity 38:4 (2013), 694–704.
33. [33] Spooner, C.J., Lesch, J., Yan, D., Khan, A.A., Abbas, A., Ramirez-Carrozzi, V., Zhou, M., Soriano, R., Eastham-Anderson, J., Diehl, L., Lee, W.P., Modrusan, Z., Pappu, R., Xu, M., DeVoss, J., Singh, H., Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat. Immunol. 14:12 (2013), 1229–1236.
34. [34] Yu, Y., Wang, C., Clare, S., Wang, J., Lee, S.C., Brandt, C., Burke, S., Lu, L., He, D., Jenkins, N.A., Copeland, N.G., Dougan, G., Liu, P., The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. J. Exp. Med. 212:6 (2015), 865–874.
35. [35] Walker, J.A., Oliphant, C.J., Englezakis, A., Yu, Y., Clare, S., Rodewald, H.R., Belz, G., Liu, P., Fallon, P.G., McKenzie, A.N., Bcl11b is essential for group 2 innate lymphoid cell development. J. Exp. Med. 212:6 (2015), 875–882.
36. [36] Zook, E.C., Ramirez, K., Guo, X., van der Voort, G., Sigvardsson, M., Svensson, E.C., Fu, Y.X., Kee, B.L., The ETS1 transcription factor is required for the development and cytokine-induced expansion of ILC2. J. Exp. Med. 213:5 (2016), 687–696.
37. [37] Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H., Furusawa, J., Ohtani, M., Fujii, H., Koyasu, S., Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463:7280 (2010), 540–544.
38. [38] Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K., Bucks, C., Kane, C.M., Fallon, P.G., Pannell, R., Jolin, H.E., McKenzie, A.N., Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464:7293 (2010), 1367–1370.
39. [39] Price, A.E., Liang, H.E., Sullivan, B.M., Reinhardt, R.L., Eisley, C.J., Erle, D.J., Locksley, R.M., Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc. Natl. Acad. Sci. U. S. A. 107:25 (2010), 11489–11494.
40. [40] McHedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A.L., Schuchmann, M., Voehringer, D., McKenzie, A.N., Neurath, M.F., Pflanz, S., Wirtz, S., Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39:2 (2013), 357–371.
41. [41] Hams, E., Armstrong, M.E., Barlow, J.L., Saunders, S.P., Schwartz, C., Cooke, G., Fahy, R.J., Crotty, T.B., Hirani, N., Flynn, R.J., Voehringer, D., McKenzie, A.N., Donnelly, S.C., Fallon, P.G., IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl. Acad. Sci. U. S. A. 111:1 (2014), 367–372.
42. [42] Roediger, B., Kyle, R., Yip, K.H., Sumaria, N., Guy, T.V., Kim, B.S., Mitchell, A.J., Tay, S.S., Jain, R., Forbes-Blom, E., Chen, X., Tong, P.L., Bolton, H.A., Artis, D., Paul, W.E., Fazekas de St Groth, B., Grimbaldeston, M.A., Le Gros, G., Weninger, W., Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat. Immunol. 14:6 (2013), 564–573.
43. [43] Mjosberg, J.M., Trifari, S., Crellin, N.K., Peters, C.P., van Drunen, C.M., Piet, B., Fokkens, W.J., Cupedo, T., Spits, H., Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12:11 (2011), 1055–1062.
44. [44] Monticelli, L.A., Sonnenberg, G.F., Abt, M.C., Alenghat, T., Ziegler, C.G., Doering, T.A., Angelosanto, J.M., Laidlaw, B.J., Yang, C.Y., Sathaliyawala, T., Kubota, M., Turner, D., Diamond, J.M., Goldrath, A.W., Farber, D.L., Collman, R.G., Wherry, E.J., Artis, D., Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12:11 (2011), 1045–1054.
45. [45] Teunissen, M.B., Munneke, J.M., Bernink, J.H., Spuls, P.I., Res, P.C., Te Velde, A., Cheuk, S., Brouwer, M.W., Menting, S.P., Eidsmo, L., Spits, H., Hazenberg, M.D., Mjosberg, J., Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol. 134:9 (2014), 2351–2360.
46. [46] Smith, S.G., Chen, R., Kjarsgaard, M., Huang, C., Oliveria, J.P., O'Byrne, P.M., Gauvreau, G.M., Boulet, L.P., Lemiere, C., Martin, J., Nair, P., Sehmi, R., Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol. 137:1 (2016), 75–86 (e8).
47. [47] Konya, V., Mjosberg, J., Innate lymphoid cells in graft-versus-host disease. Am. J. Transplant. 15:11 (2015), 2795–2801.
48. [48] Oczypok, E.A., Milutinovic, P.S., Alcorn, J.F., Khare, A., Crum, L.T., Manni, M.L., Epperly, M.W., Pawluk, A.M., Ray, A., Oury, T.D., Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cells. J. Allergy Clin. Immunol. 136:3 (2015), 747––756 e4.
49. [49] Doherty, T.A., Khorram, N., Chang, J.E., Kim, H.K., Rosenthal, P., Croft, M., Broide, D.H., STAT6 regulates natural helper cell proliferation during lung inflammation initiated by Alternaria. Am. J. Physiol. Lung Cell. Mol. Physiol. 303:7 (2012), L577–88.
50. [50] Huang, Y., Guo, L., Qiu, J., Chen, X., Hu-Li, J., Siebenlist, U., Williamson, P.R., Urban, J.F. Jr., Paul, W.E., IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential ‘inflammatory’ type 2 innate lymphoid cells. Nat. Immunol. 16:2 (2015), 161–169.
51. [51] Denney, L., Byrne, A.J., Shea, T.J., Buckley, J.S., Pease, J.E., Herledan, G.M., Walker, S.A., Gregory, L.G., Lloyd, C.M., Pulmonary epithelial cell-derived cytokine TGF-beta1 is a critical cofactor for enhanced innate lymphoid cell function. Immunity 43:5 (2015), 945–958.
52. [52] Oliphant, C.J., Hwang, Y.Y., Walker, J.A., Salimi, M., Wong, S.H., Brewer, J.M., Englezakis, A., Barlow, J.L., Hams, E., Scanlon, S.T., Ogg, G.S., Fallon, P.G., McKenzie, A.N., MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41:2 (2014), 283–295.
53. [53] Mirchandani, A.S., Besnard, A.G., Yip, E., Scott, C., Bain, C.C., Cerovic, V., Salmond, R.J., Liew, F.Y., Type 2 innate lymphoid cells drive CD4+ Th2 cell responses. J. Immunol. 192:5 (2014), 2442–2448.
54. [54] Drake, L.Y., Iijima, K., Kita, H., Group 2 innate lymphoid cells and CD4+ T cells cooperate to mediate type 2 immune response in mice. Allergy 69:10 (2014), 1300–1307.
55. [55] Maazi, H., Patel, N., Sankaranarayanan, I., Suzuki, Y., Rigas, D., Soroosh, P., Freeman, G.J., Sharpe, A.H., Akbari, O., ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity 42:3 (2015), 538–551.
56. [56] Meylan, F., Hawley, E.T., Barron, L., Barlow, J.L., Penumetcha, P., Pelletier, M., Sciume, G., Richard, A.C., Hayes, E.T., Gomez-Rodriguez, J., Chen, X., Paul, W.E., Wynn, T.A., McKenzie, A.N., Siegel, R.M., The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol. 7:4 (2014), 958–968.
57. [57] Salimi, M., Xue, L., Jolin, H., Hardman, C., Cousins, D.J., McKenzie, A.N., Ogg, G.S., Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J. Immunol. 196:1 (2016), 45–54.
58. [58] Salimi, M., Barlow, J.L., Saunders, S.P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.C., Johnson, D., Scanlon, S.T., McKenzie, A.N., Fallon, P.G., Ogg, G.S., A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210:13 (2013), 2939–2950.
59. [59] Molofsky, A.B., Van Gool, F., Liang, H.E., Van Dyken, S.J., Nussbaum, J.C., Lee, J., Bluestone, J.A., Locksley, R.M., Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43:1 (2015), 161–174.
60. [60] Duerr, C.U., McCarthy, C.D., Mindt, B.C., Rubio, M., Meli, A.P., Pothlichet, J., Eva, M.M., Gauchat, J.F., Qureshi, S.T., Mazer, B.D., Mossman, K.L., Malo, D., Gamero, A.M., Vidal, S.M., King, I.L., Sarfati, M., Fritz, J.H., Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat. Immunol. 17:1 (2016), 65–75.
61. [61] Moro, K., Kabata, H., Tanabe, M., Koga, S., Takeno, N., Mochizuki, M., Fukunaga, K., Asano, K., Betsuyaku, T., Koyasu, S., Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17:1 (2016), 76–86.
62. [62] Bjorklund, A.K., Forkel, M., Picelli, S., Konya, V., Theorell, J., Friberg, D., Sandberg, R., Mjosberg, J., The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing. Nat. Immunol. 17:4 (2016), 451–460.
63. [63] Lim, A.I., Menegatti, S., Bustamante, J., Le Bourhis, L., Allez, M., Rogge, L., Casanova, J.L., Yssel, H., Di Santo, J.P., IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213:4 (2016), 569–583.
64. [64] Silver, J.S., Kearley, J., Copenhaver, A.M., Sanden, C., Mori, M., Yu, L., Pritchard, G.H., Berlin, A.A., Hunter, C.A., Bowler, R., Erjefalt, J.S., Kolbeck, R., Humbles, A.A., Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat. Immunol. 17:6 (2016), 626–635.
65. [65] Nagakumar, P., Denney, L., Fleming, L., Bush, A., Lloyd, C.M., Saglani, S., Type 2 innate lymphoid cells in induced sputum from children with severe asthma. J. Allergy Clin. Immunol. 137:2 (2016), 624–626 e6.
66. [66] Doherty, T.A., Scott, D., Walford, H.H., Khorram, N., Lund, S., Baum, R., Chang, J., Rosenthal, P., Beppu, A., Miller, M., Broide, D.H., Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84. J. Allergy Clin. Immunol. 133:4 (2014), 1203–1205.
67. [67] Christianson, C.A., Goplen, N.P., Zafar, I., Irvin, C., Good, J.T. Jr., Rollins, D.R., Gorentla, B., Liu, W., Gorska, M.M., Chu, H., Martin, R.J., Alam, R., Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J. Allergy Clin. Immunol. 136:1 (2015), 59–68 e14.
68. [68] Barlow, J.L., Bellosi, A., Hardman, C.S., Drynan, L.F., Wong, S.H., Cruickshank, J.P., McKenzie, A.N., Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J. Allergy Clin. Immunol. 129:1 (2012), 191–198 e1–4.
69. [69] Klein Wolterink, R.G., Kleinjan, A., van Nimwegen, M., Bergen, I., de Bruijn, M., Levani, Y., Hendriks, R.W., Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur. J. Immunol. 42:5 (2012), 1106–1116.
70. [70] Kim, H.Y., Chang, Y.J., Subramanian, S., Lee, H.H., Albacker, L.A., Matangkasombut, P., Savage, P.B., McKenzie, A.N., Smith, D.E., Rottman, J.B., DeKruyff, R.H., Umetsu, D.T., Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J. Allergy Clin. Immunol. 129:1 (2012), 216–227 e1–6.
71. [71] Gauvreau, G.M., O'Byrne, P.M., Boulet, L.P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J.M., Boedigheimer, M., Davis, B.E., Dias, C., Gorski, K.S., Smith, L., Bautista, E., Comeau, M.R., Leigh, R., Parnes, J.R., Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 370:22 (2014), 2102–2110.
72. [72] Kim, B.S., Siracusa, M.C., Saenz, S.A., Noti, M., Monticelli, L.A., Sonnenberg, G.F., Hepworth, M.R., Van Voorhees, A.S., Comeau, M.R., Artis, D., TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med., 5(170), 2013 (170ra16).
73. [73] Villanova, F., Flutter, B., Tosi, I., Grys, K., Sreeneebus, H., Perera, G.K., Chapman, A., Smith, C.H., Di Meglio, P., Nestle, F.O., Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 134:4 (2014), 984–991.
74. [74] Dyring-Andersen, B., Geisler, C., Agerbeck, C., Lauritsen, J.P., Gudjonsdottir, S.D., Skov, L., Bonefeld, C.M., Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br. J. Dermatol. 170:3 (2014), 609–616.
75. [75] Saunders, S.P., Moran, T., Floudas, A., Wurlod, F., Kaszlikowska, A., Salimi, M., Quinn, E.M., Oliphant, C.J., Nunez, G., McManus, R., Hams, E., Irvine, A.D., McKenzie, A.N., Ogg, G.S., Fallon, P.G., Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J. Allergy Clin. Immunol. 137:2 (2016), 482–491.
76. [76] Hannun, Y.A., Obeid, L.M., Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9:2 (2008), 139–150.
77. [77] Buczynski, M.W., Dumlao, D.S., Dennis, E.A., Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 50:6 (2009), 1015–1038.
78. [78] Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat. Rev. Cancer 10:3 (2010), 181–193.
79. [79] Liu, D., Ji, L., Wang, Y., Zheng, L., Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein. Cardiovasc. Hematol. Disord. Drug Targets 12:2 (2012), 98–105.
80. [80] Schmidt, L.M., Belvisi, M.G., Bode, K.A., Bauer, J., Schmidt, C., Suchy, M.T., Tsikas, D., Scheuerer, J., Lasitschka, F., Grone, H.J., Dalpke, A.H., Bronchial epithelial cell-derived prostaglandin E2 dampens the reactivity of dendritic cells. J. Immunol. 186:4 (2011), 2095–2105.
81. [81] Nicolaou, A., Eicosanoids in skin inflammation. Prostaglandins Leukot. Essent. Fatty Acids 88:1 (2013), 131–138.
82. [82] Di Gennaro, A., Haeggstrom, J.Z., The leukotrienes: immune-modulating lipid mediators of disease. Adv. Immunol. 116 (2012), 51–92.
83. [83] Singh, R.K., Tandon, R., Dastidar, S.G., Ray, A., A review on leukotrienes and their receptors with reference to asthma. J. Asthma 50:9 (2013), 922–931.
84. [84] Peters-Golden, M., Henderson, W.R. Jr., Leukotrienes. N. Engl. J. Med. 57:18 (2007), 1841–1854.
85. [85] Wenzel, S.E., Larsen, G.L., Johnston, K., Voelkel, N.F., Westcott, J.Y., Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. 142:1 (1990), 112–119.
86. [86] Kim, D.C., Hsu, F.I., Barrett, N.A., Friend, D.S., Grenningloh, R., Ho, I.C., Al-Garawi, A., Lora, J.M., Lam, B.K., Austen, K.F., Kanaoka, Y., Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J. Immunol. 176:7 (2006), 4440–4448.
87. [87] Parmentier, C.N., Fuerst, E., McDonald, J., Bowen, H., Lee, T.H., Pease, J.E., Woszczek, G., Cousins, D.J., Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. J. Allergy Clin. Immunol. 129:4 (2012), 1136–1142.
88. [88] Claar, D., Hartert, T.V., Peebles, R.S. Jr., The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev. Respir. Med. 9:1 (2015), 55–72.
89. [89] Fajt, M.L., Gelhaus, S.L., Freeman, B., Uvalle, C.E., Trudeau, J.B., Holguin, F., Wenzel, S.E., Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J. Allergy Clin. Immunol. 131:6 (2013), 1504–1512.
90. [90] Hirata, T., Narumiya, S., Prostanoids as regulators of innate and adaptive immunity. Adv. Immunol. 116 (2012), 143–174.
91. [91] Nagai, H., Prostaglandin as a target molecule for pharmacotherapy of allergic inflammatory diseases. Allergol. Int. 57:3 (2008), 187–196.
92. [92] Boyce, J.A., Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol. Rev. 217 (2007), 168–185.
93. [93] Boie, Y., Rushmore, T.H., Darmon-Goodwin, A., Grygorczyk, R., Slipetz, D.M., Metters, K.M., Abramovitz, M., Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem. 269:16 (1994), 12173–12178.
94. [94] Takahashi, Y., Tokuoka, S., Masuda, T., Hirano, Y., Nagao, M., Tanaka, H., Inagaki, N., Narumiya, S., Nagai, H., Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol. 137:3 (2002), 315–322.
95. [95] Yamabayashi, C., Koya, T., Kagamu, H., Kawakami, H., Kimura, Y., Furukawa, T., Sakagami, T., Hasegawa, T., Sakai, Y., Matsumoto, K., Nakayama, M., Gelfand, E.W., Suzuki, E., Narita, I., A novel prostacyclin agonist protects against airway hyperresponsiveness and remodeling in mice. Am. J. Respir. Cell Mol. Biol. 47:2 (2012), 170–177.
96. [96] Fujimura, M., Ozawa, S., Matsuda, T., Effect of oral administration of a prostacyclin analog (OP-41483) on pulmonary function and bronchial responsiveness in stable asthmatic subjects. J. Asthma 28:6 (1991), 419–424.
97. [97] Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., Serhan, C.N., Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:7 (2001), 612–619.
98. [98] Barnig, C., Levy, B.D., Innate immunity is a key factor for the resolution of inflammation in asthma. Eur. Respir. Rev. 24:135 (2015), 141–153.
99. [99] Cooray, S.N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A.J., Flower, R.J., Perretti, M., Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. U. S. A. 110:45 (2013), 18232–18237.
100. [100] Levy, B.D., Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot. Essent. Fatty Acids 73:3–4 (2005), 231–237.
101. [101] Levy, B.D., Bonnans, C., Silverman, E.S., Palmer, L.J., Marigowda, G., Israel, E., Severe Asthma Research Program, N.H.L., Blood, I., Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172:7 (2005), 824–830.
102. [102] Planaguma, A., Kazani, S., Marigowda, G., Haworth, O., Mariani, T.J., Israel, E., Bleecker, E.R., Curran-Everett, D., Erzurum, S.C., Calhoun, W.J., Castro, M., Chung, K.F., Gaston, B., Jarjour, N.N., Busse, W.W., Wenzel, S.E., Levy, B.D., Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 178:6 (2008), 574–582.
103. [103] Christie, P.E., Spur, B.W., Lee, T.H., The effects of lipoxin A4 on airway responses in asthmatic subjects. Am. Rev. Respir. Dis. 145:6 (1992), 1281–1284.
104. [104] Wu, S.H., Chen, X.Q., Liu, B., Wu, H.J., Dong, L., Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br. J. Dermatol. 168:1 (2013), 172–178.
105. [105] Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510:7503 (2014), 92–101.
106. [106] Patel, M., Shaw, D., A review of standard pharmacological therapy for adult asthma – Steps 1–5. Chron. Respir. Dis. 12:2 (2015), 165–176.
107. [107] Walford, H.H., Lund, S.J., Baum, R.E., White, A.A., Bergeron, C.M., Husseman, J., Bethel, K.J., Scott, D.R., Khorram, N., Miller, M., Broide, D.H., Doherty, T.A., Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness. Clin. Immunol. 155:1 (2014), 126–135.
108. [108] Pelaia, G., Vatrella, A., Maselli, R., The potential of biologics for the treatment of asthma. Nat. Rev. Drug Discov. 11:12 (2012), 958–972.
109. [109] Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., Humbert, M., Katz, L.E., Keene, O.N., Yancey, S.W., Chanez, P., Investigators, M., Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371:13 (2014), 1198–1207.
110. [110] Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W., Ortega, H.G., Pavord, I.D., Investigators, S., Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371:13 (2014), 1189–1197.
111. [111] Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R., Harris, J.M., Scheerens, H., Wu, L.C., Su, Z., Mosesova, S., Eisner, M.D., Bohen, S.P., Matthews, J.G., Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365:12 (2011), 1088–1098.
112. [112] Thaci, D., Simpson, E.L., Beck, L.A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J.C., Sofen, H., Kawashima, M., Wu, R., Weinstein, S.P., Graham, N.M., Pirozzi, G., Teper, A., Sutherland, E.R., Mastey, V., Stahl, N., Yancopoulos, G.D., Ardeleanu, M., Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387:10013 (2016), 40–52.
113. [113] Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E.R., Evans, R.R., Joish, V.N., Eckert, L., Graham, N.M., Stahl, N., Yancopoulos, G.D., Louis-Tisserand, M., Teper, A., Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet, 2016.
114. [114] Townley, R.G., Agrawal, S., CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils. Ann. Allergy. Asthma. Immunol. 109:6 (2012), 365–374.
115. [115] Schuligoi, R., Sturm, E., Luschnig, P., Konya, V., Philipose, S., Sedej, M., Waldhoer, M., Peskar, B.A., Heinemann, A., CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 85:6 (2010), 372–382.
116. [116] Diamant, Z., Sidharta, P.N., Singh, D., O'Connor, B.J., Zuiker, R., Leaker, B.R., Silkey, M., Dingemanse, J., Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin. Exp. Allergy 44:8 (2014), 1044–1052.
117. [117] Barnes, N., Pavord, I., Chuchalin, A., Bell, J., Hunter, M., Lewis, T., Parker, D., Payton, M., Collins, L.P., Pettipher, R., Steiner, J., Perkins, C.M., A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin. Exp. Allergy 42:1 (2012), 38–48.